CN104364649B - 用于鉴定具有基因毒性的化合物的蛋白表达分析 - Google Patents

用于鉴定具有基因毒性的化合物的蛋白表达分析 Download PDF

Info

Publication number
CN104364649B
CN104364649B CN201380030301.2A CN201380030301A CN104364649B CN 104364649 B CN104364649 B CN 104364649B CN 201380030301 A CN201380030301 A CN 201380030301A CN 104364649 B CN104364649 B CN 104364649B
Authority
CN
China
Prior art keywords
compound
genotoxicity
expression
protein
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380030301.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104364649A (zh
Inventor
S·O·穆勒
Y·迪茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN104364649A publication Critical patent/CN104364649A/zh
Application granted granted Critical
Publication of CN104364649B publication Critical patent/CN104364649B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201380030301.2A 2012-06-13 2013-05-28 用于鉴定具有基因毒性的化合物的蛋白表达分析 Expired - Fee Related CN104364649B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659024P 2012-06-13 2012-06-13
US61/659,024 2012-06-13
PCT/EP2013/001575 WO2013185884A1 (en) 2012-06-13 2013-05-28 Protein expression analyses for identifying genotoxic compounds

Publications (2)

Publication Number Publication Date
CN104364649A CN104364649A (zh) 2015-02-18
CN104364649B true CN104364649B (zh) 2017-05-17

Family

ID=48536789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030301.2A Expired - Fee Related CN104364649B (zh) 2012-06-13 2013-05-28 用于鉴定具有基因毒性的化合物的蛋白表达分析

Country Status (9)

Country Link
US (1) US20150140123A1 (enExample)
EP (1) EP2861985B1 (enExample)
JP (1) JP6301915B2 (enExample)
CN (1) CN104364649B (enExample)
AU (1) AU2013276950B2 (enExample)
CA (1) CA2876402A1 (enExample)
ES (1) ES2660131T3 (enExample)
IL (1) IL236195B (enExample)
WO (1) WO2013185884A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9470694B2 (en) 2013-03-09 2016-10-18 Litron Laboratories Ltd. Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations
WO2014152873A1 (en) * 2013-03-14 2014-09-25 Pioma Inc. Microvesicle histone h2ax as a biomarker for genotoxic stress
CN104515760B (zh) * 2014-12-17 2017-10-31 深圳市纳观生物有限公司 双色荧光定位超分辨率生物显微方法及系统
WO2017145816A1 (ja) * 2016-02-24 2017-08-31 ソニー株式会社 光学測定器、フローサイトメータ、および放射線計数器
CN107159327B (zh) 2017-05-17 2019-04-19 京东方科技集团股份有限公司 一种生物检测芯片及其检测方法
CN110333207A (zh) * 2019-06-25 2019-10-15 中国人民解放军陆军军医大学第一附属医院 CREB在Ang-2调节VEGFR2表达中分析方法
WO2021102420A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Interferon signaling as a cancer biomarker
CN112680498A (zh) * 2020-12-28 2021-04-20 华南理工大学 一种遗传毒性物质的高通量筛查方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961080A (zh) * 2004-05-20 2007-05-09 杰特尼克斯有限公司 基因毒性检测
CN102449168A (zh) * 2009-03-28 2012-05-09 金特罗尼克斯有限公司 基因毒性测试

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480642T1 (de) * 2004-11-24 2010-09-15 Hoffmann La Roche Verfahren zur bestimmung von genotoxizität
CN101903774A (zh) * 2007-12-20 2010-12-01 弗·哈夫曼-拉罗切有限公司 预测基因毒性
DE102010024898B4 (de) * 2010-06-24 2012-10-25 Merck Patent Gmbh Genexpressionsanalysen zur Charakterisierung und Identifizierung genotoxischer Verbindungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961080A (zh) * 2004-05-20 2007-05-09 杰特尼克斯有限公司 基因毒性检测
CN102449168A (zh) * 2009-03-28 2012-05-09 金特罗尼克斯有限公司 基因毒性测试

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Biological and molecular mechanisms of sulfur mustard analogue-induced toxicity in JB6 and HaCaT cells: possible role of ataxia telangiectasia-mutated/ataxia telangiectasia-Rad3-related cell cycle checkpoint pathway;Neera Tewari-Singh et.al.;《Chem Res Toxicol》;20100514;第23卷;摘要，图3，图4 *
High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay;Paul W.Hastwell et.al.;《Mutation Research》;20060614;第607卷;第160-175页 *
High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death.;Jennifer T. Fox et.al.;《PNAS》;20120403;第109卷(第14期);图2 *
In vitro modelling of dermal absorption following enviromental or accidental exposure.;Craig Moore;《Newcastle University PhD Thesis》;20101031;第72页图3.10，第75页图3.13，第84页图3.20，第110页图4.12，第131页图5.11 *
Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX;Eike Gallmeier et.al.;《Carcinogenesis》;20050519;第26卷(第10期);图2，图3 *
p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress;Fabienne Baus et.al.;《Molecular Biology of the Cell》;20040930;第15卷;图2 *
Signalling pathways involved in 1-nitropyrene(1-NP)-induced and 3-introfluoranthene(3-NF)-induced cell death in Hepa1c1c7 cells.;Nana Asare et.al.;《Mutagenesis》;20090824;图6 *
Theα,β,γ,δ-unsaturated aldehyde 2-trans-4-trans-decadienal disturbs DNA replication and mitotic events in Early Sea Urchin embryos;Espen Hansen et.al.;《Toxicological Sciences》;20040616;第81卷;图6，第195页右侧栏第2段 *

Also Published As

Publication number Publication date
JP6301915B2 (ja) 2018-03-28
EP2861985A1 (en) 2015-04-22
IL236195B (en) 2018-07-31
CN104364649A (zh) 2015-02-18
ES2660131T3 (es) 2018-03-20
CA2876402A1 (en) 2013-12-19
US20150140123A1 (en) 2015-05-21
WO2013185884A1 (en) 2013-12-19
IL236195A0 (en) 2015-01-29
AU2013276950B2 (en) 2018-07-26
EP2861985B1 (en) 2017-11-15
JP2015521728A (ja) 2015-07-30
AU2013276950A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CN104364649B (zh) 用于鉴定具有基因毒性的化合物的蛋白表达分析
JP2024016122A (ja) Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法
US20230126657A1 (en) Compositions and Methods for Identifying and Treating Dystonia Disorders
JP2015006189A (ja) キナーゼ阻害剤のプロファイリング方法
US20190204323A1 (en) Biomarkers for pancreatic cancer
US12013406B2 (en) Methods of detecting anti-folic acid antibodies and uses thereof
JP5934183B2 (ja) ミオパチーを特性化するための組成物及び方法
JP5347028B2 (ja) バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法
AU2009313167B2 (en) Use of EEF1A as biomarker for screening of MetAP2 inhibitors
US20070264672A1 (en) Development of a novel assay for mgmt (methyl guanine methyl transferase)
JP7431226B2 (ja) レンバチニブ及びエベロリムスを含む併用療法のためのバイオマーカー
RU2745060C2 (ru) Биомаркеры для комбинированной терапии, включающей ленватиниб и эверолимус
WO2011009523A1 (en) Eg5 as biomarker in rare thoracic cancer
US20070117168A1 (en) Perinucleolar compartment as a cancer marker
US20200018750A1 (en) Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
US10809268B2 (en) Methods and kits for measuring and quantifying DNA double-stranded breaks using gamma-H2AX and H2AX
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170517

Termination date: 20190528